Literature DB >> 17291719

Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells.

Daniela Siegmund1, Stefanie Klose, Donghui Zhou, Bernd Baumann, Christian Röder, Holger Kalthoff, Harald Wajant, Anna Trauzold.   

Abstract

The CD95 and TRAIL death receptors can potently stimulate proinflammatory signalling, especially in apoptosis resistant cells. Here, we show that caspases are of cell type-specific relevance for non-apoptotic death receptor signalling in pancreatic tumour cells. Inhibition of caspases by zVAD-fmk strongly enhanced the proinflammatory response in PancTuI, BxPc3 and Panc89 cells, but inhibited this response in Colo357 cells as well as in apoptosis-resistant Colo357-BclxL cells overexpressing BclxL. To characterize the role of caspases in non-apoptotic death receptor signalling, we analysed CD95L- and TRAIL-induced signalling pathways in Colo357-BclxL cells in comparison with PancTuI cells. Both death ligands induced NFkappaB, ERKs, JNK and p38 in Colo357-BclxL cells and except for ERKs also in PancTuI cells. However, inhibition of caspases with zVAD-fmk resulted in strong inhibition of all these signalling pathways in Colo357-BclxL, but enhanced NFkappaB and JNK signalling in PancTuI cells. Caspase-mediated activation of NFkappaB and ERKs were involved in CD95L- and TRAIL-induced up-regulation of proinflammatory genes in Colo357-BclxL cells. At the level of the DISC we did not observe any significant differences in recruitment or processing of FADD, caspase-8, FLIP, TRAF2 and RIP between PancTuI and Colo357-BclxL cells. Consequently, an NFkappaB and ERK stimulating, caspase-dependent factor must operate downstream of the DISC in Colo357-BclxL cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17291719     DOI: 10.1016/j.cellsig.2006.12.008

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  23 in total

1.  Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production.

Authors:  Vera Levina; Adele M Marrangoni; Richard DeMarco; Elieser Gorelik; Anna E Lokshin
Journal:  Exp Cell Res       Date:  2008-01-16       Impact factor: 3.905

2.  TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.

Authors:  Johannes Lemke; Andreas Noack; Dieter Adam; Vladimir Tchikov; Uwe Bertsch; Christian Röder; Stefan Schütze; Harald Wajant; Holger Kalthoff; Anna Trauzold
Journal:  J Mol Med (Berl)       Date:  2010-03-31       Impact factor: 4.599

3.  HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.

Authors:  Carmella Romeo; Matthew C Weber; Mahsa Zarei; Danielle DeCicco; Saswati N Chand; Angie D Lobo; Jordan M Winter; Janet A Sawicki; Jonathan N Sachs; Nicole Meisner-Kober; Charles J Yeo; Rajanikanth Vadigepalli; Mark L Tykocinski; Jonathan R Brody
Journal:  Mol Cancer Res       Date:  2016-04-06       Impact factor: 5.852

4.  Human embryonic and induced pluripotent stem cells express TRAIL receptors and can be sensitized to TRAIL-induced apoptosis.

Authors:  Vladimir Vinarsky; Jan Krivanek; Liina Rankel; Zuzana Nahacka; Tomas Barta; Josef Jaros; Ladislav Andera; Ales Hampl
Journal:  Stem Cells Dev       Date:  2013-08-02       Impact factor: 3.272

5.  Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex.

Authors:  Shyam M Kavuri; Peter Geserick; Daniela Berg; Diana Panayotova Dimitrova; Maria Feoktistova; Daniela Siegmund; Harald Gollnick; Manfred Neumann; Harald Wajant; Martin Leverkus
Journal:  J Biol Chem       Date:  2011-03-22       Impact factor: 5.157

6.  CD95 stimulation results in the formation of a novel death effector domain protein-containing complex.

Authors:  Inna N Lavrik; Thomas Mock; Alexander Golks; Julia C Hoffmann; Simone Baumann; Peter H Krammer
Journal:  J Biol Chem       Date:  2008-07-17       Impact factor: 5.157

Review 7.  Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion.

Authors:  Sarah Shirley; Alexandre Morizot; Olivier Micheau
Journal:  Recent Pat Anticancer Drug Discov       Date:  2011-09       Impact factor: 4.169

8.  Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment.

Authors:  Peter Geserick; Mike Hupe; Maryline Moulin; W Wei-Lynn Wong; Maria Feoktistova; Beate Kellert; Harald Gollnick; John Silke; Martin Leverkus
Journal:  J Cell Biol       Date:  2009-12-28       Impact factor: 10.539

9.  Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model.

Authors:  Thorsten Heilmann; Anna-Lena Rumpf; Marijke Roscher; Maren Tietgen; Olga Will; Mirko Gerle; Timo Damm; Christoph Borzikowsky; Nicolai Maass; Claus-Christian Glüer; Sanjay Tiwari; Anna Trauzold; Christian Schem
Journal:  Arch Gynecol Obstet       Date:  2020-03-14       Impact factor: 2.344

10.  Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction.

Authors:  Paola Secchiero; Federica Corallini; Claudio Ceconi; Giovanni Parrinello; Stefano Volpato; Roberto Ferrari; Giorgio Zauli
Journal:  PLoS One       Date:  2009-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.